Wire · opportunities
Zai Lab's zoci takes FDA orphan drug designation for neuroendocrine carcinomas
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 August 2026 · Fusion42 review
Zai Lab's zocilurtatug pelitecan (zoci) has received FDA orphan drug designation for a broader indication of neuroendocrine carcinomas (NECs) beyond pulmonary NECs. This regulatory status provides incentives including tax credits, user-fee exemptions, and seven years of US market exclusivity if approved, supporting its ongoing Phase III trial and collaborations.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now position your biotech pipeline around zoci’s expanded FDA orphan designation to pursue NEC treatment markets underserved by standard care. Expect accelerated development incentives and a clearer US market path that might reshape competitive differentiation against other DLL3-targeting therapies.
◆ Coverage
1 source · 4 Aug 2026
◆ Related on Wire
◆ Topics